Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGB002
- Development stage
- Preclinical
- Lead developer
- BerGenBio
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
BGB002 is a preclinical small molecule inhibitor developed by BerGenBio, with preclinical development support from Sygnature Discovery. It targets a novel, undisclosed protein that mediates aggressive, drug-resistant tumors, epithelial-to-mesenchymal transition (EMT), and cancer stem cell traits. The target was identified using BerGenBio's proprietary CellSelect RNAi® screening technology.
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on BGB002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGB002.